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Abstract 
Tumor cells require angiogenesis to deliver nutrients and oxygen to support their fast growth and 
metabolism. The vascular endothelial growth factor (VEGF) pathway plays an important role in 
promoting angiogenesis, including tumor-induced angiogenesis. Recent clinical trials have 
demonstrated the benefit of targeting VEGF in the treatment of glioblastoma. However, the 
prognostic significance of the expression of VEGFA and its receptors VEGFR1 (FLT1) and VEGFR2 
(KDR) are still largely elusive. In the present study, we aimed to investigate the prognostic signif-
icance of these three factors, alone or in combination, in glioma patients. Gene mRNA expression 
was extracted from three independent brain tumor cohorts totaling 242 patients and the asso-
ciation between gene expression and survival was tested. We found that when VEGFA, FLT1 and 
KDR expressions were considered alone, only VEGFA demonstrated a significant association with 
patient survival. Patients with high expression of both VEGFA and either receptor had significantly 
worse survival than patients expressing both factors at a low level. Importantly, we found that 
those patients whose tumors overexpressed all three genes had a significantly shorter survival 
compared to those patients with a low level expression of these genes. Our results suggest that a 
high level expression of VEGFA and its receptors, both FLT1 and KDR, may be required for brain 
tumor progression, and that these three factors should be considered together as a prognostic 
indicator for brain tumor patients. 
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Introduction 
Gliomas are the most common type of primary 
brain tumors, of which grade 3 astrocytoma and grade 
IV glioblastoma are highly malignant and are associ-
ated with a very poor prognosis [1]. As with other 
malignancies, the growth and development of glio-
mas is reliant on the angiogenic process. VEGF is an 
important factor promoting tumor angiogenesis, and 
the activation of VEGF pathway requires the binding 
of the ligand, such as VEGFA, to one of its receptors, 
such as FLT1 or KDR, thus generating downstream 
signals to stimulate the proliferation and structural 
reorganization of endothelial cells [2]. The VEGF 
family is divided into four members, including 
VEGFA, VEGFB, VEGFC and VEGFD, and VEGF re-
ceptors consist of three subtypes, including VEGFR1 
(FLT1), VEGFR2 (KDR), and VEGFR3 [3]. VEGFA is a 
key regulator of developmental vasculogenesis and 
angiogenesis and it mainly interacts with FLT1 and 
KDR to generate downstream signaling [3]. FLT1 is a 
tyrosine kinase receptor that binds VEGFA with about 
10-fold higher affinity than KDR, and although it is 
poorly activated by VEGF ligands, it has been shown 
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to promote tumor growth and metastasis [3]. On the 
other hand, VEGF ligand binding to KDR, also a tyro-
sine kinase receptor, generates potent downstream 
signals that leads to endothelial cell growth and mi-
gration [3]. The development of targeted therapy for 
malignant glioma has had limited success mainly due 
to the parallel and converging complex interactions 
between several important pathways, including 
pathways that regulate tumor angiogenesis [4].  
VEGF, FLT1 and KDR, were all shown to be 
up-regulated in brain tumor vasculature [5], signify-
ing the importance of angiogenesis in glioma. Sup-
pressing expression of VEGF in tumoral cells by an-
ti-sense RNA technology was shown to inhibit the 
growth of glioma cells in vivo in nude mice [6]. In 
addition, VEGF also plays an important role in angi-
ogenesis induced by stem cell-like glioma cells [7]. 
Inhibition of angiogenesis acts synergistically with 
chemotherapy in reducing the tumor sphere forming 
ability of brain tumor stem-like cells in glioma xeno-
graft model [8]. Together, these results suggest that 
the VEGF pathway plays a central role in initiation 
and progression of glioma, especially in the glioma 
stem cells. 
 Bevacizumab is a monoclonal antibody that 
binds to VEGFA and neutralizes VEGFA from bind-
ing to FLT1 and KDR, thereby inhibiting the down-
stream growth signal that could induce angiongenesis 
[9]. Indeed, bevacizumab has been shown to be effec-
tive in combination with irinotecan for recurrent high 
grade glioma with a radiographic response noted in 
around 60% of patients, and a 6-month overall sur-
vival of 77% in patients treated with this regimen [10, 
11]. Other phase II trials have shown and confirmed 
that bevacizumab as a single agent or in combination 
with irinotecan are active and tolerable in patients 
with recurrent glioblastoma [12, 13]. The Food and 
Drug Administration in United States approved 
bevacizumab as a single agent in patients with gli-
obastoma multiforme (GBM) whose disease had pro-
gressed following prior therapy[14]. Recently, the 
results from a phase II study reported that bevaci-
zumab in combination with lomustine has clinical 
activity to recurrent GBM [15]. Two studies have as-
sessed the potential of bevacizumab for the treatment 
of newly diagnosed glioblastoma. Combination of 
bevacizumab with temozolomide and radiation 
therapy increased progression-free survival compared 
to a retrospective control cohort [16], while combina-
tion of bevacizumab with other chemotherapeutic 
agents may improve efficacy in newly diagnosed gli-
oblastoma [17]. The results from two Phase III studies 
have confirmed that addition of bevaicumab to radi-
otherapy and chemotherapy led to improvement in 
progression-free survival but not overall survival [18, 
19]. 
 VEGFA, FLT1 and KDR mRNAs are expressed at 
an elevated level in malignant tumor endothelial 
compared to normal brain vasculature [20]. Overex-
pression of VEGFA, but not FLT1, was seen in 
high-grade astrocytoma compared to low-grade as-
trocytoma [21], while increased expression of FLT1 
was observed in grade 4 diffusely infiltrating astro-
cytomas [22]. Very recently, a SNP located in the 5’ 
UTR of the VEGFA gene, was demonstrated to be as-
sociated with higher plasma VEGFA concentration 
and a longer progression-free survival in GBM pa-
tients treated with bevacizumab [23].  
Despite the unquestionable role of angiogenesis 
in progression of malignancies of the brain, and de-
spite recognition of VEGF pathway-targeting treat-
ment strategies, expression profiling of the VEGF 
pathway role-players for brain tumor prognostication 
has not been done. Recently, we demonstrated the 
prognostic value of combined expression profiling of 
VEGFA, FLT1 and KDR in lung and colon cancers, in 
which anti-VEGF therapy has been shown to be effec-
tive. In the present study, we aimed to investigate the 
prognostic significance of these three factors in com-
bination in glioma, whose most malignant subtype, 
glioblastoma, is susceptible to bevacizumab. 
Materials and Methods 
Extraction of clinical and microarray gene ex-
pression data from glioma patient datasets  
Three glioma patient datasets, GSE4271 [24], 
GSE4412 [25] and GSE7696 [26] were identified in the 
Gene Expression Omnibus (GEO) Database; datasets 
using the HG-U133 microarray platform, and com-
prising >70 patients for whom survival data were 
available were included in this study. Microarray 
gene expression data were retrieved from the data 
matrixes deposited to the GEO database by the origi-
nal authors. R scripting was used to extract the ex-
pression values from probesets of VEGFA, FLT1 and 
KDR, and the clinical data from the data matrixes 
downloaded from GEO as previously described [27].  
Patient stratification 
Expression levels were divided into four groups 
using quartile as the cut-off points for association 
analysis. The median expression level was used as the 
cut-off point for survival analysis. Patients were fur-
ther divided into three groups based on the expres-
sion levels of VEGFA and FLT1; the VEGFA-FLT1-low 
group consisted of patients who expressed both of 
these two genes at low levels; the VEGFA-FLT1-high 
group consisted of patients who expressed both of 
these two genes at high levels; the 
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VEGFA-FLT1-intermediate group consisted of the rest 
of patients; patients were similarly stratified into 
VEGFA-KDR subgroups. Patients were also divided 
into four groups based on the number of genes, 
among VEGFA, FLT1 and KDR, that were expressed at 
a high level. 
Correlations of gene expression levels and 
clinical data 
Since the sample size was small, the three patient 
cohorts were combined and analyzed together. The 
combined brain tumor dataset comprised 258 pa-
tients, 231 of whose survival data were available. Of 
these 231 patients, 175 were deceased at data 
collection. Of the 231 samples, 186 were glio-
blastoma, and the remaining 45 were of other 
subtypes. All statistical analyses were per-
formed using SPSS19.0. The associations be-
tween expression levels of genes were tested by 
Chi-Square test. For Kaplan-Meier survival 
analysis, results were compared by log-rank test. 
Cox regression analysis was used to correlate 
the gene expression levels and patient survival. 
Results 
The prognostic significance of VEGFA, 
FLT1 and KDR in glioma patients  
The prognostic significance of VEGFA, 
FLT1 and KDR was tested in a combined dataset 
comprising a total of 231 patients from GSE4271, 
GSE4412 and GSE7696. Using median expres-
sion level as a cut-off point, we found that pa-
tients whose tumors expressed a high level of 
VEGFA had a mean survival of 23 months (95% 
CI = 18 – 28 months), while those whose tumors 
expressed a low level of VEGFA had a mean 
survival of 46 months (95% CI = 37 – 54 months), 
with a Hazard ratio of 1.86 (95% CI = 1.38 – 2.52, 
p < 0.001; Figure 1A). This result suggests that a 
high level of VEGFA in glioma specimens pre-
dicted a shorter survival time of glioma patients. 
On the other hand, the survival time was not 
significantly different between patients whose 
tumors expressed different levels of FLT1 (p = 
0.624; Figure 1B) or KDR (p = 0.379; Figure 1C). 
Together, our results suggest that VEGFA is a 
better prognostic factor for glioma patients.  
Association between VEGFA, FLT1 and 
KDR expression 
FLT1 expression level was significantly 
different among patients expressing various 
levels of VEGFA (Chi Square test, p < 0.001; 
Figure 2A). Around 11% (25 out of 231) of pa-
tients expressed both VEGFA and FLT1 at a very 
high level and around 10% (23 out of 231) of 
patients expressed both VEGFA and FLT1 at a 
low level, while only 3% (6 out of 231) of pa-
tients who expressed VEGFA at a low level ex-
pressed FLT1 at a very high level and only 6% 
(13 out of 231) of patients who expressed VEGFA 
 
Figure 1. The association between VEGFA mRNA expression and brain 
tumor patient survival. Kaplan-Meier analyses for mRNA expression of (A) 
VEGFA (B) FLT1 and (C) KDR in the brain tumor patient cohort consisting of 231 
patients. P-value for log-rank test is presented alongside each Kaplan-Meier plot.  
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at a very high level expressed FLT1 at a low level. 
Similar results were observed when the association 
between VEGFA and KDR expression levels was 
tested (Chi Sqaure test, p = 0.037; Figure 2B). Merely 
3% (6 out of 231) of patients who expressed VEGFA at 
a low level expressed KDR at a very high level, but 
around 18% patients expressed these two genes both 
at a very high level or both at a low level. The expres-
sion levels between the two receptors, FLT1 and KDR, 
were significantly associated (Chi Square test, p < 
0.001; Figure 2C). As shown in Figure 2C, only 4% 
patients expressed FLT1 at a low level and KDR at a 
very high level, and vice versa, but 29% of patients 
expressed FLT1 and KDR at a very high level, and at a 
low level, respectively. Our results suggest that these 
three factors were co-expressed at a high level in 
glioma specimens leading us to further investigate the 
prognostic significance of the co-expression of these 
factors. 
High level expression of both VEGFA and 
FLT1 mRNA in the same patients predicts 
shorter survival outcome 
Although FLT1 alone did not predict patient 
survival in our combined glioma dataset, the molec-
ular mechanism for VEGFA-FLT1 signaling led us to 
hypothesize that glioma patients whose tumors ex-
pressed high levels of both VEGFA and FLT1 may 
have the worst prognosis. To investigate this hypoth-
esis, we stratified the patients into three groups based 
on the levels of expression of VEGFA and FLT1. As 
shown in Figure 3, patients whose tumors expressed 
both VEGFA and FLT1 at low levels had a mean sur-
vival of 43 months (32 – 53 months), patients whose 
tumors expressed one of these two genes at high level 
had a mean survival of 37 months (28 – 46 months), 
and patients whose tumors expressed both genes at 
high level had a mean survival of 24 months (18 – 31 
months), which was significantly shorter than that of 
the VEGFA-FLT1-low group of patients (p = 0.017). 
Patients whose tumors expressed both genes at high 
level had a significantly higher risk of death than 
those whose tumors expressed both genes at low level 
with a hazard ratio of 1.57 (95% CI = 1.06 – 2.31, p = 
0.023). Our results suggest that glioma patients whose 
tumors co-expressed VEGFA and FLT1 at a high level 
had a poorer prognosis.  
High level expression of both VEGFA and KDR 
mRNA in the same patients predicts shorter 
survival outcome 
Similarly, although KDR alone did not predict 
patient survival in our combined glioma dataset, the 
co-overexpression of VEGFA and KDR may be im-
portant for activation of such signals. We stratified the 
patients into three groups based on the levels of ex-
pression of VEGFA and KDR. As shown in Figure 4, 
patients whose tumors expressed both VEGFA and 
KDR at low levels had a mean survival of 48 months 
(36 – 59 months), patients whose tumors expressed 
one of these two genes at high level had a mean sur-
vival of 35 months (27 – 44 months), and patients 
whose tumors expressed both genes at high level had 
 
Figure 2. The association between VEGFA, FLT1 and KDR 
mRNA expression in brain tumor patients. Histograms showing the 
percentage of patients whose tumor expressed different levels of (A) 
VEGFA and FLT1, (B) VEGFA and KDR and (C) FLT1 and KDR.  
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a mean survival of 24 months (17 – 30 months), which 
was significantly shorter than the VEGFA-KDR-low 
group of patients (p = 0.001). Patients whose tumors 
expressed both genes at high level had a significantly 
higher risk of death than those whose tumors ex-
pressed both genes at low level with a hazard ratio of 
1.94 (95% CI = 1.30 – 2.92, p = 0.001). Our results sug-
gest that glioma patients whose tumor co-expressed 
VEGFA and KDR at a high level had a poorer prog-
nosis.  
High level expression of VEGFA, FLT1 and 
KDR mRNA in the same patients predicts 
shorter survival outcome 
Since both FLT1 and KDR could be activated 
upon binding by its ligand, VEGFA, we then investi-
gated whether the co-expression of these three factors 
have value in patient prognosis. Interestingly, we 
found that patient survival time shortened with in-
creasing number of VEGF pathway genes overex-
pressed. As shown in Figure 5, patients whose tumors 
expressed none of these three genes at a high level 
had a mean survival time of 43 months (95% CI = 30 – 
57 months), patients whose tumors expressed one of 
these three genes at a high level had a mean survival 
time of 39 months (95% CI = 29 – 50 months), patients 
whose tumors expressed two of these three genes at a 
high level had a mean survival time of 30 months 
(95% CI = 22 – 38 months), and patients whose tumors 
expressed all three genes at a high level had a mean 
survival time of 26 months (95% CI = 19 – 34 months), 
which was significantly shorter than group of patients 
who expressed all three genes to a low degree. Im-
portantly, patients whose tumors expressed all three 
genes at a high level had a higher risk of death com-
pared to those whose tumors expressed none of these 
three genes at a high level (Hazard Ratio = 1.56, 95% 
CI = 0.98 – 2.47, p = 0.06). Together, our results suggest 
that co-overexpression of VEGFA and its two recep-
tors, FLT1 and KDR, in glioma biopsies is a prognostic 
indicator for glioma patients.  
 
 
Figure 3. The association between combination of VEGFA-FLT1 mRNA expression and brain tumor patient survival. Kaplan-Meier 
analyses for VEGFA and FLT1 mRNA expression in combination in the brain tumor patient cohort 
 
Figure 4. The association between combination of VEGFA-KDR mRNA expression and brain tumor patient survival. Kaplan-Meier 
analyses for VEGFA and KDR mRNA expression in combination in the brain tumor patient cohort 
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Figure 5. The association between combination of VEGFA-FLT1-KDR mRNA expression and brain tumor patient survival. 
Kaplan-Meier analyses for VEGFA, FLT1 and KDR mRNA expression in combination in the brain tumor patient cohort. 
 
Discussion 
 Anti-angiogenesis has been shown to be an ef-
fective strategy in treatment of patients with glio-
blastoma, the most aggressive type of glioma. Previ-
ously, we have shown that the co-overexpression of 
VEGFA and its receptors, FLT1 and KDR, is associated 
with poor prognosis in both lung and colon cancers 
[28, 29], malignancies that benefit from an-
ti-angiogenesis therapy. Interestingly, in the present 
study, we have shown that co-expression of these 
genes also confers prognostic significance in glioma, 
suggesting that VEGFA-FLT1-KDR three-gene signa-
ture may be a potential prognostic indicator for glio-
ma patients. We previously reported that expression 
profiling of this three-gene signature could also pre-
dict response to bevacizumab in colon cancer patients 
[29]. Bevacizumab is an anti-angiogenic agent that has 
also been shown to be effective in glioblastoma pa-
tients; as no dataset comprising glioblastoma patients 
who have received bevacizumab exist in the public 
domain, and as there is also a lack of success in iden-
tification of biomarker for anti-angiogenic agents [30], 
the value of this three-gene signature for prediction of 
response to bevacizumab in glioblastoma patients 
warrants further investigation.  
Tumor angiogenesis is a highly dynamic process 
that is controlled by the interaction between tumor 
and endothelial cells as well as the tumor microenvi-
ronment and is required for tumor growth, invasion, 
and metastasis [31]. Activation of a cell surface re-
ceptor requires the presence of its ligand, however, 
overexpression of the ligand alone may not be suffi-
cient to drive sufficient signaling to promote cancer 
progression. Overexpression of a cell surface receptor, 
such as HER2, has been shown to be sufficient to 
promote breast cancer progression and predict tumor 
response to anti-HER2 therapy [32]. In addition, mu-
tation that led to constitutive activation of a cell sur-
face receptor, EGFR, was found to be sufficient to 
promote lung cancer progression and predict tumor 
response to EGFR tyrosine kinase inhibitors [33]. In 
the present report, we have demonstrated the im-
portance of considering the co-overexpression of both 
the ligand, VEGFA, and its receptors, FLT1 and KDR, 
in prognosis of glioma patients.  
Glioblastoma is a very aggressive subtype of 
glioma with very short life expectancy and limited 
treatment options. Although anti-angiogenesis has 
been shown to be effective in delaying tumor pro-
gression in glioblastoma patients, mixed results on 
other clinical endpoints in phase III trials studying 
bevacizumab in newly diagnosed glioblastoma pa-
tients suggest that not all patients will be benefit from 
anti-angiogenic therapy [18, 19]. Similarly, mixed re-
sults have also been observed in phase III trials in 
lung [34, 35] and colon cancers [36, 37]. Together with 
our previous findings in lung and colon cancer patient 
cohorts [28, 29], our results suggest that this 
three-gene signature may have clinical application in 
terms of predicting response towards anti-angiogenic 
agents in various types of cancer, and that this war-
rants further clinical evaluation, especially in a pro-
spective trial setting.  
Since glioblastoma patients have only limited 
treatment options, bevacizumab, which has been 
shown to relieve symptoms related to brain tumor, 
could be a valuable option to them. However, the 
clinical use with bevacizumab is still hindered by the 
lack of a suitable biomarker for identifying a 
sub-population of patients that could definitely bene-
fit from treatment of bevacizumab. Although we have 
been unable to determine the anti-angiogenesis re-
sponse-prediction capacity of this three-gene signa-
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ture in glioblastoma patients, we have validated its 
use for predicting patient morbidity, and encourage 
others who may have access to data on glioblastoma 
patient response to bevacizumab to test the value of 
the three-gene signature for predicting response to the 
therapy. 
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